Logo image
Dofetilide and Flecainide Combination: The Serendipity of Successful Treatment of Atrial Fibrillation After Failed Ablation
Journal article   Peer reviewed

Dofetilide and Flecainide Combination: The Serendipity of Successful Treatment of Atrial Fibrillation After Failed Ablation

Daniel A. N. Mascarenhas and Bharat K. Kantharia
Canadian journal of cardiology, v 41(2), pp 212-214
01 Feb 2025
PMID: 39549951

Abstract

Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Life Sciences & Biomedicine Science & Technology
Antiarrhythmic drugs (AADs) and catheter ablation (CA) are guideline-directed rhythm control treatments for atrial fibrillation (AF). AADs are rarely used in combination to treat AF. Dofetilide (class III agent) and flecainide (class Ic agent) are contraindicated in patients with renal dysfunction and coronary artery disease, respectively. We describe a case of a patient who refused nonpharmacological treatment for recurrent AF after CA, but was treated successfully with a dofetilide and flecainide combination. The patient's taking the combination was serendipitous initially. Both drugs were continued nonetheless, because it was the combination and not the individual drug that controlled AF in our patient.

Metrics

1 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Cardiac & Cardiovascular Systems
Logo image